← Product Code [JPA](/productcode/JPA) · K260909

# Sonoclot Coagulation & Platelet Function Analyzer System with Sonoclot Viewer (SCP1); Sonoclot Coagulation & Platelet Function Analzyer System with Sonoclot Viewer (SCP2); Sonoclot Coagulation Analyzer System with Sonoclot Viewer (SC1) (K260909)

_Sienco, Inc. · JPA · Oct 27, 2026 · Hematology · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K260909

## Device Facts

- **Applicant:** Sienco, Inc.
- **Product Code:** [JPA](/productcode/JPA.md)
- **Decision Date:** Oct 27, 2026
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 864.5425
- **Device Class:** Class 2
- **Review Panel:** Hematology

## Indications for Use

The Sonoclot Analyzer System is an in vitro diagnostic device for measuring coagulation and platelet function. This system configuration is a Sonoclot Analyzer connected to a computer running Sonoclot Viewer data collection software. The Sonoclot Analyzer System rapidly provides information on the entire hemostasis process including coagulation, fibrin gel formation, clot retraction (platelet function) and fibrinolysis. The Sonoclot Analyzer System generates a qualitative graph, known as the Sonoclot Signature, and quantitative results on the clot formation time (Activated Clotting Time-Onset), the rate of fibrin polymerization (Clot Rate), and clot retraction (Platelet Function). This information can be used to identify numerous coagulopathies including platelet dysfunction, factor deficiencies, anticoagulant effect, hypercoagulable tendencies and hyperfibrinolysis. Different disposable tests are available for use with the Sonoclot Analyzer System for different applications.

## Device Story

Sonoclot Coagulation & Platelet Function Analyzer System (models SC1, SCP1, SCP2) performs coagulation and platelet function analysis; utilizes mechanical viscoelastometry to measure clot formation; updated with modern circuitry and new enclosures; SCP1 is single-channel analyzer; SCP2 is two-channel version; SC1 is single-channel with platelet function analysis disabled; used in clinical settings to monitor hemostasis; provides quantitative results to clinicians for coagulation management.

## Clinical Evidence

Bench testing only; design verification and validation activities performed based on risk analysis to confirm performance of updated circuitry and enclosures.

## Technological Characteristics

Mechanical viscoelastometry; updated electronic circuitry; new analyzer enclosures; multi-channel (1 or 2 channel) configurations; software-controlled analysis.

## Regulatory Identification

A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.

## Special Controls

*Classification.* Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

## Predicate Devices

- Sonoclot Coagulation & Platelet Function Analyzer System with Sonoclot Viewer ([K223635](/device/K223635.md))
- Sonoclot Coagulation & Platelet Function Analyzer System with Signature Viewer Option ([K002528](/device/K002528.md))
- Sonoclot Coagulation & Platelet Function Analyzer ([K952560](/device/K952560.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{1}

[LOGO]

FDA

U.S. FOOD & DRUG

ADMINISTRATION

# SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

## I Background Information:

### A 510(k) Number

K260909

### B Applicant

Sienco, Inc.

### C Proprietary and Established Names

Sonoclot Coagulation & Platelet Function Analyzer System with Sono Viewer (SCP1)
Sonoclot Coagulation & Platelet Function Analyzer System with Sonoclot Viewer (SCP2)
Sonoclot Coagulation Analyzer System with Sonoclot Viewer (SC1)

### D Regulatory Information

|  Product Code(s) | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  JPA | II | 864.5425 | Hematology  |

## II Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable.

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.)
2. Submitter's statement that the INDICATIONS FOR USE/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to

Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

{2}

demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. The changes to the existing device includes:

a) Models SC1, SCP1, and SCP2 have been updated to use modern circuitry and analyzer enclosures.
b) The models available have been expanded from one model to three models. Model SCP1 is a direct update of model DP-2951. Model SC1 is identical to model SCP1 with the exception that platelet function results have been disabled. Model SCP2 is a two channel version of model SCP1.
4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.
5. A Design Control Activities Summary which includes:
a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.

K251968 - Page 2 of 2

---

**Source:** [https://fda.innolitics.com/device/K260909](https://fda.innolitics.com/device/K260909)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
